Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
recombinant neutrophil inhibitory factor + bivalirudin
- Development stage
- Unknown
- Lead developer
- Shandong New Era Pharmaceutical
- Modality
- Peptides, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Administration
- Intravenous
01
Overview
rNIF-Hirulog (NY-101) is a recombinant fusion protein developed by Shandong New Era Pharmaceutical (a subsidiary of Lunan Pharmaceutical Group) for the treatment of acute ischemic stroke. This bifunctional molecule combines a recombinant neutrophil inhibitory factor (rNIF) with bivalirudin (Hirulog). The rNIF component, originally derived from the hookworm *Ancylostoma caninum*, is a potent antagonist of the Mac-1 integrin (CD11b/CD18), which prevents neutrophil adhesion to the vascular endothelium and reduces inflammatory tissue damage. The bivalirudin component is a direct thrombin inhibitor that provides anticoagulant activity by binding to both the active site and exosite I of thrombin. By simultaneously inhibiting neutrophil-mediated inflammation and thrombin-mediated thrombosis, rNIF-Hirulog aims to reduce ischemia-reperfusion injury and improve clinical outcomes in stroke patients. The drug has progressed to Phase 2 clinical trials in China.
- Other names
- recombinant neutrophil inhibitory factor + hirulogrNIF-HirulogrNIF-bivalirudinrNIF-bivalirudin fusion protein
02
Targets
F2 (Thrombin)αMβ2 (Integrin αMβ2)
Beyond the preview
Go deeper on recombinant neutrophil inhibitory factor + bivalirudin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on recombinant neutrophil inhibitory factor + bivalirudin.